Pontifax is a healthcare-dedicated venture capital firm that invests in transformative, cutting-edge life sciences technologies at all development stages. The firm backs breakthrough innovation across therapeutic areas, both by establishing its own companies and by partnering with existing management teams to nurture startups to maturity.
32% of their portfolio is in Biotech & Life Sciences. Deal activity increased 67% year-over-year (5 deals in the last 12 months). Their most common stage is series-b (43% of deals). Average disclosed round size is $76.3M (across 45 rounds with reported amounts).
Portfolio
48
Fund Size
—
Top Stage
Series B
Last 12 Mo
8
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
56 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| PPrecirix | Series B | — | Aug 2026 |
| CCrystalys Therapeutics | Series B | $130M | Jul 2026 |
| CCrystalys Therapeutics Inc | Series B | $130M | Jul 2026 |
| AAdcendo ApS | Series C | $75M | Apr 2026 |
 Adcytherix | Series A | — | Oct 2025 |
 Step Pharma | Series C | — | Oct 2025 |
 Crystalys | Series A | $205M | Sep 2025 |
| CCrystalys Therapeutics Inc | Series A | $205M | Sep 2025 |
| AAbcuro, Inc. | Series C | $200M | Feb 2025 |
| LLutris Pharma | Unknown | $30M | Jan 2025 |
 Adcendo | Series B | $135M | Nov 2024 |
 Indapta Therapeutics | Unknown | $22.5M | Jan 2024 |
 PRECIRIX NV | Series B | — | Mar 2022 |
| EEmergence Therapeutics | Series A | — | Dec 2021 |
 Antios Therapeutics | Series B | $75M | Nov 2021 |
| AAntios Therapeutics, Inc. | Series A | $75M | Nov 2021 |
 Theseus Pharmaceuticals | Series B | $100M | Apr 2021 |
| AAntios Therapeutics, Inc. | Series B | $96M | Apr 2021 |
 Stride Bio | Series B | $81.5M | Mar 2021 |
| SStrideBio | Series B | $81.5M | Mar 2021 |
 EyeYon | Series C | $25M | Mar 2021 |
 Agomab Therapeutics | Series B | $74M | Mar 2021 |
| AAntios Therapeutics, Inc. | Series B | $96M | Jan 2021 |
| SStargazer Pharmaceuticals | Series A | $57M | Nov 2020 |
 V-Wave | Series C | $98M | Sep 2020 |
Page 1 of 3
Top Co-Investors
OrbiMed15 shared
RA Capital Management15 shared
Alexandria Venture Investments9 shared
Soleus Capital8 shared
Kurma Partners6 shared
Adage Capital Management6 shared
Foresite Capital6 shared
Novo Holdings A/S5 shared
Bpifrance5 shared
Andera Partners5 shared
Surveyor Capital5 shared
HealthCap5 shared
Triventures5 shared
DSC Investment5 shared
Regeneron Pharmaceuticals5 shared
Consensus Business Group5 shared
Dawn Biopharma4 shared
Delos Capital4 shared
Sixty Degree Capital4 shared
Last updated: 8 September 2026